Brought to you by 
Biogen, Ionis pen sixth CNS agreement; could be worth in excess of $1bn
Apr 2018
Executive Summary
Partners Biogen Inc. and Ionis Pharmaceuticals Inc. have formed a new ten-year deal aimed at developing new antisense therapies for a wide range of neurological conditions.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Intra-Biotech Deal
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen, Ionis pen sixth CNS agreement; could be worth in excess of $1bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice